Welcome to our dedicated page for NewAmsterdam Pharma Company N.V news (Ticker: NAMS), a resource for investors and traders seeking the latest updates and insights on NewAmsterdam Pharma Company N.V stock.
NewAmsterdam Pharma Company N.V. reports news on its late-stage clinical biopharmaceutical work in oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C. The company’s principal program centers on obicetrapib, an oral, low-dose CETP inhibitor, evaluated alone and as a fixed-dose combination with ezetimibe as an adjunct to statin therapy.
Recurring updates include Phase 3 clinical data from programs such as BROADWAY, TANDEM, BROOKLYN and PREVAIL, safety and tolerability analyses, regulatory-review activity, financial results, corporate presentations and scientific-conference disclosures. NewAmsterdam also reports Nasdaq inducement grants and other equity-compensation actions tied to its public-company governance.
NewAmsterdam Pharma Company N.V. completed its business combination with Frazier Lifesciences Acquisition Corporation on November 22, 2022. The transaction generated approximately $328 million in gross proceeds, including $235 million from an upsized private investment in public equity (PIPE). This financing is expected to extend the company's cash runway through 2026, covering pivotal Phase 3 trials for cardiovascular disease treatments. Trading under the new ticker symbols NAMS and NAMSW commenced on November 23, 2022.